Holland 1999.

Methods	Study design: Randomised controlled trial
Participants	Diagnosis: DSM ‐ III ‐ R panic disorder with or without agoraphobia Method of diagnosis: Not stated Age: for adinazolam, M = 36.5; for clomipramine, M = 35.8; SD not provided Sex: for adinazolam, 36% male; for clomipramine 38% male Location: UK; setting unclear Co‐morbidities: patients with psychiatric co‐morbidities were excluded Rescue medication: Not stated
Interventions	Participants were randomly assigned to either: (1) adinazolam arm (n = 166) Duration: 24 weeks Treatment Protocol: flexible dosage; range = 30 ‐ 90 mg, M and SD not provided (2) clomipramine arm (n = 149) Duration: 24 weeks Treatment Protocol: flexible dosage; range = 50 ‐ 150 mg, M and SD not provided
Outcomes	Time points for assessment: weeks 1, 2, 4, 8, 12, 16, 20 and 24 Outcomes: 1. total number of panic attacks (Panic Attack and Anticipatory Anxiety scale) 2. Clinical Global Impression Improvement Score (CGI‐I) 3. SCL ‐ 90, Phobic Anxiety Dimension 4. Sheehan Disability Scale
Notes	Date of study: Not stated Funding source: Not stated Declarations of interest among the primary researchers: Not stated.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomized".
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "double‐blind". No further details.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "double‐blind". No further details.
Incomplete outcome data (attrition bias) All outcomes	High risk	LOCF data are reported, but without specifying number of patients evaluated.
Selective reporting (reporting bias)	Unclear risk	All outcomes were reported, but without specifying number of patients evaluated.
Other bias	Unclear risk	Authors' affiliations refer to pharmaceutical companies.